Alliance for Pandemic Preparedness

September 21, 2020

Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial

Category:

Topic:

Keywords (Tags):

  • Of 38 hospitalized COVID-19 patients who received convalescent plasma in Connecticut and Massachusetts, 24 (63%) recovered and were discharged, and 14 (37%) died. Sixteen patients (42%) with severe illness who received plasma early in disease progression had lower mortality (13% vs. 55%, p<0.02) and shorter mean hospital length of stay (15.4 vs. 33 days, p<0.01) than 22 patients (58%) with critical illness who receive plasma later. One patient experienced a transient transfusion reaction. No other adverse effects were observed.

Ibrahim et al. (Sept 20, 2020). Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-020-00341-2